The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | C-POST: adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma
Danny Rischin, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the Phase III C-POST trial (NCT03969004) of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery and radiation. Cemiplimab significantly prolonged disease-free survival and reduced both local-regional and distant recurrences compared to placebo. Clinical benefit was consistent across PD-L1 subgroups. Safety findings were manageable and in line with expectations. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The C-POST Phase III trial took a group of patients that were at very high risk of recurrence, cutaneous SCC, after surgery and radiotherapy and randomised them to cemiplimab or placebo. The key finding from the trial is there was a marked reduction in recurrence in the patients who received cemiplimab. So the improvement in disease-free survival had a hazard ratio of 0...
The C-POST Phase III trial took a group of patients that were at very high risk of recurrence, cutaneous SCC, after surgery and radiotherapy and randomised them to cemiplimab or placebo. The key finding from the trial is there was a marked reduction in recurrence in the patients who received cemiplimab. So the improvement in disease-free survival had a hazard ratio of 0.32, the P-value less than 0.0001, so a 68% reduction. And this benefit in terms of reduced recurrences was seen in all pre-specified subgroups, both what we call nodal and non-nodal high risk groups. There was a benefit that was seen both in a dramatic decrease in local regional recurrences, an 80% reduction, and a decrease in distant metastases of a 65% reduction. The treatment was well tolerated, the safety profile was as one has seen previously with the well-established toxicity profile of cemiplimab monotherapy. So the conclusion in terms of efficacy was there was a marked improvement in disease-free survival that was statistically significant and clinically meaningful, and it’s the first systemic adjuvant treatment to improve outcomes for patients with high-risk, locally, radically advanced, cutaneous squamous cell carcinoma, and is likely to represent a potential new standard of care for these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
